AFDO Cyclospora: Part two — regulatory approach


This follow-up presentation will focus on FDA response to positive cyclospora findings. FDA will review our process and objectives during follow-up to a positive finding, provide an overview of investigative priorities, summarize some of the challenges to addressing cyclospora contamination, and the process for coordinating with state partners to protect public health, including the documents that FDA would need in order to consider taking compliance action.


Joann Givens, U.S. Food and Drug Administration (FDA); Crystal McKenna, U.S. Food and Drug Administration (FDA); and Maria Knirk, U.S. Food and Drug Administration (FDA)


June 5, 2020